Gout: The State of the Science

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Improving Patient Outcomes

• Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial (abstract 0952)
• A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study (abstract 0677)
• Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate (abstract 0683)
• The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout (abstract 0685)

Systemic Burden of Disease

• Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis (abstract 0648)
• Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study (abstract 0681)
• Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study (abstract 0662)
• Change in Tophus Size Measured with Dual-Energy CT and Ultrasound: A 1-year Multicenter Follow-up Study (abstract 1550)
• Gout and Heart Failure in the U.S. (abstract 0657)
• Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure (abstract 0673)

Watch this page for details on these and other new studies, or visit the ACR’s Meeting Abstracts site.